구조모아 (StructureMoa)항암 chemical structure spider web
방문Iovance Biotherapeutics
분석
큐레이션 브리핑
경쟁 포지션: Only approved TIL product; opens the solid-tumor cell-therapy category.
기전. Autologous TILs already primed against the patient's tumor are expanded to therapeutic numbers, reinfused after lymphodepletion to clear regulatory cells and cytokine sinks, then supported with IL-2.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Polyclonal tumor neoantigens (TIL)
Unresectable or metastatic melanoma after PD-1 blockade
US
Approved
amtagvi · lifileucel · Amtagvi · LN-144 · tumor infiltrating lymphocyte
2026-09-10
Data Confidence · High
Development Signal · Established
Autologous tumor-infiltrating lymphocyte (TIL) therapy
No gene editing — TILs are harvested from resected tumor, expanded ex vivo with IL-2, and reinfused
Tumor resection → centralized 22-day expansion → single infusion
Polyclonal recognition of private neoantigens instead of one engineered receptor, so it does not depend on a single shared target.
구조화 데이터
Polyclonal recognition of private neoantigens instead of one engineered receptor, so it does not depend on a single shared target.
Antigen presentation loss (B2M/HLA), TIL exhaustion, and a hostile tumor microenvironment.
Autologous tumor-infiltrating lymphocyte (TIL) therapy
Polyclonal tumor neoantigens (TIL) · Tumor mutational burden and baseline tumor burden correlate with response; no required companion diagnostic.
Manage lymphodepletion and IL-2 related toxicity in an experienced center
Only approved TIL product; opens the solid-tumor cell-therapy category.
Advanced melanoma progressing on a PD-1 inhibitor and, if BRAF V600-mutant, a BRAF/MEK inhibitor
Post-IO salvage
Single IV infusion after non-myeloablative lymphodepletion, followed by high-dose IL-2
One-time
ORR ~31% in C-144-01
Manage lymphodepletion and IL-2 related toxicity in an experienced center
Only approved TIL product; opens the solid-tumor cell-therapy category.
Autologous TILs already primed against the patient's tumor are expanded to therapeutic numbers, reinfused after lymphodepletion to clear regulatory cells and cytokine sinks, then supported with IL-2.
Polyclonal TCR repertoire against private neoantigens; durable tumor infiltration in responders.
MHC-restricted, TCR-mediated killing of autologous tumor cells.
Tumor mutational burden and baseline tumor burden correlate with response; no required companion diagnostic.
Antigen presentation loss (B2M/HLA), TIL exhaustion, and a hostile tumor microenvironment.
구조화 데이터
Human
Cell persistence, not plasma pharmacokinetics
TIL persistence in blood and tumor; radiographic response duration
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (advanced melanoma)
APPROVAL · 2024년 2월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Iovance Biotherapeutics
분석
큐레이션 브리핑
경쟁 포지션: Only approved TIL product; opens the solid-tumor cell-therapy category.
기전. Autologous TILs already primed against the patient's tumor are expanded to therapeutic numbers, reinfused after lymphodepletion to clear regulatory cells and cytokine sinks, then supported with IL-2.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Polyclonal tumor neoantigens (TIL)
Unresectable or metastatic melanoma after PD-1 blockade
US
Approved
amtagvi · lifileucel · Amtagvi · LN-144 · tumor infiltrating lymphocyte
2026-09-10
Data Confidence · High
Development Signal · Established
Autologous tumor-infiltrating lymphocyte (TIL) therapy
No gene editing — TILs are harvested from resected tumor, expanded ex vivo with IL-2, and reinfused
Tumor resection → centralized 22-day expansion → single infusion
Polyclonal recognition of private neoantigens instead of one engineered receptor, so it does not depend on a single shared target.
구조화 데이터
Polyclonal recognition of private neoantigens instead of one engineered receptor, so it does not depend on a single shared target.
Antigen presentation loss (B2M/HLA), TIL exhaustion, and a hostile tumor microenvironment.
Autologous tumor-infiltrating lymphocyte (TIL) therapy
Polyclonal tumor neoantigens (TIL) · Tumor mutational burden and baseline tumor burden correlate with response; no required companion diagnostic.
Manage lymphodepletion and IL-2 related toxicity in an experienced center
Only approved TIL product; opens the solid-tumor cell-therapy category.
Advanced melanoma progressing on a PD-1 inhibitor and, if BRAF V600-mutant, a BRAF/MEK inhibitor
Post-IO salvage
Single IV infusion after non-myeloablative lymphodepletion, followed by high-dose IL-2
One-time
ORR ~31% in C-144-01
Manage lymphodepletion and IL-2 related toxicity in an experienced center
Only approved TIL product; opens the solid-tumor cell-therapy category.
Autologous TILs already primed against the patient's tumor are expanded to therapeutic numbers, reinfused after lymphodepletion to clear regulatory cells and cytokine sinks, then supported with IL-2.
Polyclonal TCR repertoire against private neoantigens; durable tumor infiltration in responders.
MHC-restricted, TCR-mediated killing of autologous tumor cells.
Tumor mutational burden and baseline tumor burden correlate with response; no required companion diagnostic.
Antigen presentation loss (B2M/HLA), TIL exhaustion, and a hostile tumor microenvironment.
구조화 데이터
Human
Cell persistence, not plasma pharmacokinetics
TIL persistence in blood and tumor; radiographic response duration
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (advanced melanoma)
APPROVAL · 2024년 2월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.